Author Archives: Administrator

A Phase 1, Double-blind, Placebo-controlled, Randomized, Two-Part, Ascending Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Rejuveinix (RJX) in Healthy Participants. Click here for the full study details

Reven successfully completes Phase I clinical trials and is pleased to announce completion with no Serious Adverse Events and no Unexpected Adverse Events.  Results are expected to be submitted to the FDA during the next few weeks.

Reven announces Phase II Clinical Development plans for upcoming human efficacy trials.  These trials include exploring efficacy as an adjunct therapy for patients suffering Critical Limb Ischemia.  Additional areas of focus in separate trials will be for chronic wound healing … Read More

Reven will soon kick off a social media campaign to get the word out about the exciting developments relative to RJX moving through the regulatory pathway. Please seek us out on Facebook, Instagram, Twitter, LinkedIn and like/comment on our posts … Read More

Kevin McGovern Joins Reven’s Board of Directors. Reven announces Kevin McGovern as the newest addition to its Board of Directors. Kevin McGovern Press Release

Reven Hires Dr. James Carlson. Dr. James Carlson hired as Reven’s Executive Vice President of Development Dr. James Carlson Press Release here: Reven Press Release – 011719  

On January 15, 2019 Reven completed their single-ascending-dose (SAD)/ multiple-ascending-dose (MAD) Phase 1 Clinical Trial in the United States. Reven is now in the planning stage of their Phase 2 Clinical Trial that will be conducted in the United States … Read More

MAD Cohort 3 completed dosing on January 15, 2019.

Reven Hires Susan Moore. Susan Moore hired as Reven’s Senior Director of Regulatory and Clinical Affairs.

MAD Cohort 3 begins seven-day dosing period.

Reven Hires Natalie Pizzimenti. Natalie Pizzimenti hired as Reven’s Clinical Research Scientist.

MAD Cohort 2 completed dosing on December 18, 2018.

MAD Cohort 2 begins seven-day dosing period.

SAD Cohort 6C doses subjects; SAD Cohort 6 is completed.